Prostate-specific antigen forms a complex with and cleaves α1-protease inhibitor in vitro

Prostate

Volumn 33, Issue 2, 1997, Pages 87-96

  Zhang, Wan Ming ^a   Leinonen, Jari ^a   Kalkkinen, Nisse ^b   Stenman, Ulf Håkan ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

protease inhibitor; Complex formation; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ARTICLE; FEMALE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOFLUORESCENCE TEST; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ALPHA 1-ANTICHYMOTRYPSIN; ALPHA 1-ANTITRYPSIN; ALPHA-MACROGLOBULINS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOBLOTTING; ISOENZYMES; MALE; PROSTATE-SPECIFIC ANTIGEN; TIME FACTORS;

EID: 0030868806     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19971001)33:2<87::AID-PROS2>3.0.CO;2-J     Document Type: Article

References (44)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate-specific antigen. Invest Urol 1979;17:159-163.
2. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 1990;144:1550-1556.
3. Frazier HA, Humphrey PA, Burchette JL, Paulson DF: Immunoreactive prostate specific antigen in male periurethral glands. J Urol 1992;147:246-248.
4. Takayama TK, Vessella RL, Brawer MK, True LDF, Noteboom J, Lange PH: Urinary prostate specific antigen levels after radical prostatectomy. J Urol 1994;151:82-87.
5. Kamoshida S, Tsutsumi Y: Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 1990;21:1108-1111.
6. Yu H, Diamandis EP, Sutherland DJA: Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-79.
7. Lilja H: A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903.
8. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R: Human prostate specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
9. Schaller J, Akiyama K, Tsuda R, Marti T, Rickli EE: Isolation, characterization and amino-acid sequence of γ-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987; 170:111-130.
10. Lilja H, Oldbrink J, Rannevik G, Laurell CB: Seminal vesicle secreted proteins and their reactions during gelation and lique-faction of human semen. J Clin Invest 1987;80:281-285.
11. Lilja H, Abrahamsson PA, Lundwall A: Seminogelin, the predominant protein in human semen: Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989;264:1894-1899.
12. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194:755-763.
13. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
14. Espana F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A: Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complex with prostate-specific antigen. Thromb Res 1991;64:309-320.
15. Espana F, Sanchez CJ, Vera CD, Estelles A, Gilabert J: A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 1993;122:711-719.
16. Christensson A, Lilja H: Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994;220:45-53.
17. 1-antitrypsin. J Med 1985;16:23-99.
18. Vercaigne MD, Davril M, Laine A, Hayem A: Interaction of human alpha-1-proteinase inhibitor with human leukocyte cathepsin G. Biol Chem Hoppe Seyler 1985;366:655-661.
19. 1-antitrypsin and bovine α-chymotrypsin. J Biochem (Tokyo) 1979;86:915-921.
20. 1-antitrypsin. J Biochem (Tokyo) 1978;83:269-277.
21. Leinonen J, Lövgren T, Vornanen T, Stenman U-H: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and the complex between prostate-specific antigen with α-1-antichymotrypsin. Clin Chem 1993;39:2098-2103.
22. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL: Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993;39:2483-2491.
23. Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H: Purification and characterization of different molecular forms of prostate specific antigen in human seminal fluid. Clin Chem 1995;41:1567-1573.
24. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-1625.
25. Laemmli UK: Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
26. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1971;76: 4350-4354.
27. Leinonen J, Zhang WM, Stenman U-H: Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996;155: 1099-1103.
28. Kalkkinen N, Tilgmann C: A gas-pulsed-liquid-phase sequencer constructed from a Beckman 890D instrument by using Applied Biosystems delivery and cartridge blocks. J Protein Chem 1988; 7:242-243.
29. 1-proteinase inhibitor using zinc chelate chromatography. Anal Biochem 1979;99:415-420.
30. Stenman U-H, Leinonen J, Zhang WM: Standardization of PSA determination. Scand J Clin Lab Invest [Suppl] 1995;55:45-51.
31. 1-antitrypsin. Nature 1982;298:329-334.
32. 1-antitrypsin. Nature 1984;312:77-80.
33. 1-proteinase inhibitor. J Biol Chem 1978; 20:7142-7144.
34. 1-antitrypsin) by elastase. Biochim Biophys Acta 1977;482:400-411.
35. 1-proteinase inhibitor by thiol proteinase. Biochem J 1977;163:639-641.
36. 1-antitrypsin, chymotrypsin and human leukocyte elastase as revealed by end group analysis. Biochim Biophys Acta 1981;667:328-340.
37. 1-proteinase inhibitor with porcine trypsin. Biochim Biophys Acta 1982;704:221-226.
38. Henttu P, Lukkarinen O, Vihko P: Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer 1990;45:654-660.
39. Wang TJ, Finlay JA, Mikolajczyk S, Rittenhouse HG, Wolfert RL: Analysis of cross-reactivity of anti-PSA monoclonal antibodies with recombinant human glandular kallikrein [abstract]. J Urol 1996;155:695.
40. Henttu P, Vihko P: cDNA coding for the entire prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun 1989;160:903-910.
41. Riegman P, Vliestra R, van der Korput J, Romijn J, Trapman J: Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem Biophys Res Commun 1989;159:95-102.
42. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocardinoma of the prostate. N Engl J Med 1987;317:909-916.
43. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
44. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-105.